NICE accepts aripiprazole for bipolar disorder in adolescents

NICE has approved the use of aripiprazole (Abilify) in adolescents with bipolar I disorder for treating moderate to severe manic episodes.

Abilify is also approved by NICE for treating schizophrenia in patients aged 15 to 17 years when risperidone is unsuitable.
Abilify is also approved by NICE for treating schizophrenia in patients aged 15 to 17 years when risperidone is unsuitable.

The atypical antipsychotic aripiprazole (Abilify) is recommended by NICE for use within its licensed indication in adolescents aged 13 years and over for up to 12 weeks.

It is also approved for use on the NHS by NICE for treating schizoprenia in patients aged 15–17 years when risperidone is contraindicated, not tolerated or does not provide adequate symptom control.

View Abilify drug record

NICE guidance on aripiprazole for treating moderate to severe manic episodes in adolescents with bipolar I disorder

Follow MIMS on Twitter


MIMS Clinics

Prescribing news and resources for key therapeutic areas, collated by the MIMS editors.

Register or Subscribe to MIMS

GPs can get MIMS print & online and GPonline for free when they register online – take 2 minutes, and make sure you get your free MIMS access! If you're not a GP, you can subscribe to MIMS for full access.

Register or subscribe

MIMS bulletins

News and updates straight to your inbox.

Prescribing Update: Fortnightly news bulletin
Alert:
Urgent prescribing updates
Spotlight: Disease-themed monthly round-up

Sign me up

MIMS Dermatology

Read the latest issue online exclusively on MIMS Learning.

Read MIMS Dermatology

Mobile apps

MIMS: access the full drug database and quick-reference tables on the go

MIMS Diagnosis and Management: concise information on signs and symptoms, investigations and diseases

Promo Image

Clinical calculators

Handy calculators and conversions for primary care.